Cotazym Market Report 2026

Cotazym Market Overview

• The Cotazym market growth in the historic period has been driven by clinical acceptance of enzyme replacement therapies, rising cystic fibrosis prevalence • Market expansion is supported by growth in chronic pancreatitis cases, expanding geriatric population • Growth Driver: Rising Gastrointestinal Disease Prevalence Drives Growth Of The Cotazym Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cotazym Market?

Cotazym is a brand name for an enzyme preparation that typically contains a mixture of pancreatic enzymes, primarily amylase, lipase, and protease. These enzymes help break down carbohydrates, fats, and proteins in the digestive system, assisting in digestion and nutrient absorption, particularly in individuals with pancreatic insufficiency. The main types of indications in cotazym are capsules or tablets and powder form. Capsules and tablets refer to two common forms of oral medications, each designed to deliver drugs in a specific way. It is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies, catering to various therapeutic applications, including cystic fibrosis, chronic pancreatitis, and pancreatic diseases.

What Is The Cotazym Market Growth Forecast?

The growth in the forecast period can be attributed to growth in chronic pancreatitis cases, expanding geriatric population, improved access to digestive care therapies, rising focus on nutrition optimization, expansion of specialty gastroenterology clinics. Major trends in the forecast period include rising demand for pancreatic enzyme replacement therapy, growing diagnosis of pancreatic insufficiency disorders, increased focus on digestive health management, expansion of long term enzyme supplementation use, improved formulations for better nutrient absorption.

Global Cotazym Market Segmentation

1) By Formulation: Capsules Or Tablets, Powder Form 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies 3) By Therapeutic Application: Cystic Fibrosis, Chronic Pancreatitis, Pancreatic Diseases

What Are The Drivers Of The Cotazym Market?

The increasing prevalence of gastrointestinal diseases is expected to propel the growth of the cotazym market going forward. Gastrointestinal diseases refer to a broad range of conditions that affect the digestive system, including the stomach, intestines, liver, pancreas, and other associated organs. The rising prevalence of gastrointestinal diseases can be attributed to poor dietary habits, such as high consumption of processed foods, and the increasing obesity rates, both of which contribute to the development of various digestive disorders. Cotazyme, a digestive enzyme supplement, aids gastrointestinal disease patients by enhancing nutrient absorption and alleviating digestive discomfort through its targeted support for enzyme deficiencies, thereby improving overall gut health and function. For instance, in September 2023, according to the National Institutes of Health (NIH), a US-based government agency, the prevalence of Inflammatory Bowel Disease (IBD) in Canada is estimated at 825 cases per 100,000 people, meaning over 320,000 individuals are affected. This prevalence is expected to increase by 2.44% annually, reaching 1.1% of the population, or 470,000 Canadians, by 2035. Therefore, the increasing prevalence of gastrointestinal diseases is driving the growth of the cotazym industry. The rising demand for biological products is expected to propel the growth of the cotazyme market going forward. Biological products refer to complex pharmaceutical substances derived from living organisms, used to diagnose, prevent, treat, and cure diseases and medical conditions. The rise in demand for biological products is attributed to growing environmental concerns, heightened consumer awareness, and the need for sustainable and effective alternatives to synthetic chemicals. Cotazyme enhances the effectiveness and sustainability of biological products by optimizing enzymatic reactions, improving process efficiency, and ensuring higher yields, thereby contributing to the overall performance and cost-effectiveness of biotechnological applications. For instance, in October 2025, according to the US Food and Drug Administration, a US-based federal agency of the Department of Health and Human Services, as of 2024, the FDA has approved 76 biosimilars, representing only a small portion of all approved biologics. In comparison, over 30,000 generics have been approved, surpassing the total number of approved brand-name drugs. Therefore, a rise in demand for biological products drives the cotazyme market. The rising prevalence of rare genetic disorders is anticipated to drive the growth of the cotazym market going forward. Genetic disorders are medical conditions caused by abnormalities in an individual’s DNA, such as mutations in genes or changes in chromosome structure or number. The rising prevalence of rare genetic disorders is due to advances in diagnostic technologies, which enable better detection, and increased awareness, leading to higher reporting rates. Cotazyme supports patients with rare genetic disorders, such as cystic fibrosis, by providing essential pancreatic enzymes that aid in the digestion and absorption of nutrients, addressing the malabsorption issues caused by exocrine pancreatic insufficiency commonly associated with these conditions. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, 11,148 people were living with cystic fibrosis (CF) in the UK in 2022, increasing to 11,318 in 2023. Therefore, the rising prevalence of rare genetic disorders is anticipated to drive the growth of the cotazym industry.

Key Players In The Global Cotazym Market

Major companies operating in the cotazym market are Organon & Co.

Regional Insights

North America was the largest region in the cotazym market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cotazym Market?

The cotazym market consists of sales of products including non-capsulated cotazyme, and cotazyme forte. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cotazym Market Report 2026?

The cotazym market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cotazym industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.